摘要

Over the past decade, transcatheter aortic valve replacement (TAVR) matured from an adventitious endeavor in the early years to an established and paradigm-changing treatment option for many patients with severe aortic valve stenosis. %26lt;br%26gt;However, lack of long-term data on device performance as well as the obvious presence of procedure-specific complications currently limit the expansion of this technology toward lower-risk patients outside controlled and randomized clinical trials.

  • 出版日期2012-5